Physician profile
David D Buethe
NPI 1013069186
$3,690.70
in general payments reported to CMS, 2019-2025
30 companies · $543 in 2025
The $543 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $226 · 2021: $873 · 2022: $672 · 2023: $422 · 2024: $708 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,128.11 | 2020-2024 | Axonics, Bulkamid |
| Coloplast Corp | $454.48 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $388.90 | 2020-2025 | |
| Astellas Pharma US INC | $250.83 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $205.15 | 2019-2024 | Aveed, Xiaflex |
| Procept Biorobotics Corporation | $192.45 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Medtronic, INC. | $167.37 | 2021 | |
| Urogen Pharma, INC. | $120.02 | 2020-2023 | Jelmyto |
| Karl Storz Endoscopy-America | $87.60 | 2022 | |
| Telix Pharmaceuticals | $73.43 | 2024-2025 | Illuccix |
| Calyxo, INC. | $72.23 | 2025 | Cvac Aspiration System |
| 180 Medical, INC. | $48.65 | 2020-2023 | |
| Janssen Biotech, INC. | $47.63 | 2023-2025 | Erleada |
| Medtronic USA, INC. | $42.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.29 | 2022-2023 | Welireg, Keytruda |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $38.55 | 2024 | Provenge |
| Blue Earth Diagnostics | $37.96 | 2024 | |
| Tolmar, INC. | $33.40 | 2025 | Eligard |
| Tolmar Pharmaceuticals, INC. | $30.15 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $27.56 | 2024 | |
| C. R. Bard, INC. & Subsidiaries | $25.67 | 2019 | |
| Allergan, INC. | $23.34 | 2019-2021 | |
| Abbvie INC. | $21.72 | 2022 | |
| Myovant Sciences INC. | $20.92 | 2021 | |
| Ambu INC. | $20.80 | 2025 | |
| Accord Healthcare, INC. | $20.74 | 2023 | |
| Teleflex LLC | $20.26 | 2022 | |
| Boston Scientific Corporation | $19.04 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.56 | 2025 | Adstiladrin |
| Caldera Medical, INC | $13.61 | 2023 | Desara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Buethe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.